Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±ºñ´ëÁõ¿¡¼­ °æ¿äµµÀü¸³¼±Ä§Æı«¼úÀÇ Ãʱâ°æÇè Early Experiences of the Transurethral Needle Ablation(TUNA) in BPH

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 1È£ p.63 ~ 67
±èÅÂÈ¿, ¾ÈÅ¿µ, ÇϽÂÀÏ,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÅÂÈ¿ (  ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

¾ÈÅ¿µ (  ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
ÇϽÂÀÏ (  ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
ÇϺοä·ÎÁõ»óÀ» ÀÏÀ¸Å°´Â Àü¸³¼±ºñ´ëÁõÀÇ Ä¡·á¿¡ ÀÖ¾î Áö±Ý±îÁö´Â °æ¿äµµÀü¸³¼±ÀýÁ¦¼úÀÌ
Ç¥ÁØÄ¡·á·Î ¾Ë·ÁÁ® ÀÖÀ¸³ª ÃÖ±Ù ´ú ħ½ÀÀûÀ̸鼭 È¿°úÀûÀÎ »õ·Î¿î Ä¡·á¹ýÀÇ °³¹ßÀ» À§ÇÑ ¸¹
Àº ½Ãµµ°¡ ÀÌ·ç¾îÁ® ¿Ô´Ù. ÀÌ·¯ÇÑ ´ëü¿ä¹ýÀÇ ÀÏȯÀ¸·Î ¥á-blocked, finasteride µîÀ» ÀÌ¿ëÇÑ
¾à¹°¿ä¹ý, Àü¸³¼±¿äµµ ½ºÅÙÆ®À¯Ä¡¼ú, dz¼±È®Àå¼ú, Àü±â±âÈ­¼ú, ·¹ÀÌÀúÀü¸³¼±ÀýÁ¦¼ú, ¿Â¿­¿ä¹ý,
°í¿Â¿­Ä¡·á, high-intensity focused ultrasound(HIFU) ¹× °æ¿äµµÀü¸³¼±Ä§Æı«¼ú(TUNA) µî
ÀÌ °³¹ßµÇ¾î ¿ÔÀ¸¸ç microwave, ultrasound, laser ±×¸®°í ¹æ»çÁÖÆÄ(radiofreqency, RF) µî
¿©·¯°¡Áö ¿¡³ÊÁö¸¦ ÀÌ¿ëÇÏ¿© ºñ´ëµÈ Àü¸³¼±Á¶Á÷³»¿¡ ¿­À» °¡ÇÏ¿© Á¶Á÷À» Æı«ÇÏ´Â ¿­Ä¡·á¹ý
¿¡ ´ëÇÑ Á¤È®ÇÑ ±âÀüÀº ¾ÆÁ÷±îÁö ºÒ¸íÈ®ÇÏ´Ù. ÇöÀç±îÁö Á¦½ÃµÇ°í ÀÖ´Â ¿­Ä¡·á¹ýÀÇ ±âÀüÀ¸·Î
´Â ºñ´ëµÈ Àü¸³¼±Á¶Á÷ÀÇ ÇغÎÇÐÀû ±¸Á¶ÀÇ À§Ãà°ú ¹è´¢±â´ÉÀÇ »ý¸®Àû º¯È­¸¦ ÀÏÀ¸Å°´Â °ÍÀ¸
·Î »ý°¢µÇ°íÀÖ´Ù.
TUNAÄ¡·á¹ýÀº ÀÌ·¯ÇÑ ¿­Ä¡·á¹ýµé Áß ÃÖ±Ù¿¡ °³¹ßµÈ °ÍÀ¸·Î ³·Àº ¼öÁØÀÇ RF¿¡³ÊÁö¸¦ ÀÌ
¿ëÇÏ¿© Àü¸³¼±ºñ´ëÁõÀ» Ä¡·áÇÏ´Â °£ÆíÇϸ鼭µµ ÀÌȯÀ²ÀÌ ³·Àº ´ëü¿ä¹ýÀ¸·Î ÀÌ¿¡ »ç¿ëµÈ
RF¿¡³ÊÁö´Â º»·¡ ½ÉÀå³»°ú¿Í ½Å°æ¿Ü°ú¿¡¼­ ¿µ¿ª¿¡¼­ Wolff-Parkinson-White ÁõÈıº ȯÀÚ
ÀÇ ÀÌ»ó Àüµµ·ÎÀÇ Á¤È®ÇÑ ÀýÁ¦ ¹× ÀÌ»ó ½Å°æÀü´Þ°æ·ÎÀÇ ÀýÁ¦¿¡ »ç¿ëµÇ¾î ¿Ô¾ú´Ù. Àü¸³¼±ºñ
´ëÁõ¿¡ ÀÖ¾î TUNA Ä¡·á¹ýÀº ¿äµµ, ¹æ±¤ ±×¸®°í Á÷Àå µî ÁÖÀ§Àå±â ¹× Á¶Á÷¿¡ ¼Õ»óÀ» ÁÖÁö
¾Ê°í 100-110¡É±îÁö ¿Âµµ¸¦ ¿Ã·Á¼­ Àü¸³¼±½ÇÁú ³»ºÎº´º¯ÀÇ ÇÑÁ¤µÈ ºÎÀ§¿¡ ±¹ÇÑµÈ ÀÀ°í¼º
±«»ç¸¦ ÀÏÀ¸Å°¸ç ÀÌ¿¡ ÀÇÇØ Àü¸³¼±ºñ´ëÁõÀÇ ÁÖ°üÀû Áõ»ó ¹× °´°üÀû ÁöÇ¥ÀÇ È£ÀüÀ» °¡Á®¿Â´Ù
°í º¸°íµÇ°í ÀÖ´Ù.
ÀÌ¿¡ ÀúÀÚµéÀº ÇϺοä·ÎÁõ»óÀÌ ÀÖ´Â Àü¸³¼±ºñ´ëÁõ ȯÀڵ鿡¼­ TUNA Ä¡·á¹ýÀ» ½ÃÇàÇÏ¿©
±× È¿°ú¿Í ¾ÈÀü¼º¿¡ °üÇÑ Ãʱâ ÀÓ»ó°æÇèÀ» º¸°íÇÑ´Ù.

Purpose: TUNA is a new minimally invasive treatment modality for the patients with
benign prostatic hyperplasia of prostate utilizing low levels of radiofrequency energy. We
presented our early experiences of TUNA for the treatment of BPH to evaluate its
clinical out come.
Materials and Methods: From July 1995 to March 1997, 36 patients were treated with
TUNA(15 with manual system, 21 with automatic system). Mean age of the patients
was 63.5 years. All patients were evaluated preoperatively with PSA, AUA symptom
score, uroflowmetry and transrectal ultrasonography (TRUS). AUA symptom score at 1,
3, 12 month and uroflowmetry at 1, 3 month postoperatively were available for analysis.
Results: Mean PSA value was 3.4ng/§¢ and mean prostate volume by TRUS was
35.5gram preoperatively. Nine out of 36 procedures were performed with local anesthesia.
Mean operating time was 45.6 minutes. At postoperative 3 and 12 month, symptom
score was improved from 22.0¡¾1.5 to 11.7¡¾1.6 and 11.0¡¾1.9(p<0.05), respectively and
maximal flow rate was increased from 11.2¡¾0.7§¢/sec to 14.4¡¾1.5§¢/sec at postoperative
3 month(p<0.05). Results have been far better since using automatic system.
Complications were observed in one patient with clot retention and in 11 patients with
postoperative urinary retention.
Conclusions: TUNA is a simple, safe, efficacious and minimally invasive treatment
procedure with short hospital stay, less morbidity for treatment of the patients with
BPH. It could also be performed with local anesthesia. We suggest that TUNA would
be a new promising treatment modality for BPH.

Å°¿öµå

Benign prostatic hyperplasia; Thermotherapy; Transurethral needle ablation;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS